Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

  • There is currently no data for BMK

Directorate Change

29 Nov 2023 07:01

RNS Number : 9803U
Benchmark Holdings PLC
29 November 2023
 

29 November 2023

 

Benchmark Holdings plc

("Benchmark" or the "Company")

Directorate Change

The Company is pleased to announce the appointment of Jonathan Esfandi as Non-Executive Director. Mr Esfandi is the founder and managing partner at JNE Partners LLP. 

Mr. Esfandi will act as shareholder representative of JNE Partners LLP, a significant shareholder of the Company, and therefore the Board has concluded that he is not an independent director. 

Laura Lavers, who joined the Board in November 2022, will retire from the Board as a Non-Executive Director with effect from today.

 

Peter George, Chairman, commented:

"We welcome Jonathan to the Board and look forward to working together. On behalf of the Board, I wish to thank Laura Lavers for her contribution over the past year."

The following information is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies in connection with the appointment of Jonathan to the Board of the Company:

Full Name: Jonathan Esfandi

Age: 49

Current Directorships: 

JNE PARTNERS LLP

JNE PARTNERS (UK) SERVICES LTD

Former Directorships (previous five years): None within the past five years

Beneficial interest in the equity securities of Benchmark Holdings plc: No direct beneficial interest. Funds managed by JNE Partners LLP have a holding of 169,263,811 shares in Benchmark

There is no further information required to be disclosed under Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

Enquiries

For further information, please contact:

Benchmark Holdings plc

Tel: 0114 240 9939

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations

Deutsche Numis (Nominated Adviser and Broker)

Tel: 020 7260 1000

Freddie Barnfield, Duncan Monteith, Sher Shah

MHP

Tel: 020 3128 8004

Katie Hunt, Reg Hoare

benchmark@mhpgroup.com

 

Equity Development

Hannah Crowe

 

Tel: 020 7065 2692

 

About Benchmark

Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADXBDBXGDDGXI
Date   Source Headline
19th Mar 20217:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
26th Feb 202110:52 amRNSTotal Voting Rights
22nd Feb 20217:00 amRNSQ1 Results
9th Feb 202112:43 pmRNSResult of AGM
9th Feb 20217:00 amRNSNotice of Q1 Results
29th Jan 20217:00 amRNSTotal Voting Rights
13th Jan 20217:00 amRNSIssue of Equity
8th Jan 20211:13 pmRNSReplacement: DIRECTOR SHARE OPTIONS
8th Jan 20219:57 amRNSDIRECTOR SHARE OPTIONS
6th Jan 20213:45 pmRNSDirector Dealings
31st Dec 20207:00 amRNSTotal Voting Rights
11th Dec 20205:32 pmRNSPosting of Annual Report and Notice of AGM
2nd Dec 20202:09 pmRNSDirector Dealings
1st Dec 20204:02 pmRNSAnnual Financial Report
1st Dec 202011:30 amRNSDirector Dealings
1st Dec 202010:30 amRNSDirector Dealings
1st Dec 202010:21 amRNSPCA Dealing
30th Nov 20207:00 amRNSTotal Voting Rights
27th Nov 20207:00 amRNSQ4 Results
27th Nov 20207:00 amRNSFull Year Results
18th Nov 20207:00 amRNSDirectorate Change
4th Nov 20207:00 amRNSInvestor Presentation for Retail Investors
30th Oct 20207:00 amRNSTotal Voting Rights
27th Oct 20207:00 amRNSNotice of Results
13th Oct 20202:29 pmRNSHolding(s) in Company
12th Oct 20202:50 pmRNSHolding(s) in Company
30th Sep 20207:00 amRNSTotal Voting Rights
29th Sep 20207:00 amRNSHolding(s) in Company
21st Sep 20207:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
11th Sep 20205:58 pmRNSHolding(s) in Company
10th Sep 20209:15 amRNSPositive Opinion from the EMA on BMK08
4th Sep 20207:00 amRNSDirector/PDMR Shareholding
28th Aug 20207:00 amRNSTotal Voting Rights
28th Aug 20207:00 amRNSQ3 Results
21st Aug 20207:00 amRNSNotice of Q3 Results
31st Jul 202011:17 amRNSCompletion of sale of vaccine facility
31st Jul 20207:00 amRNSTotal Voting Rights
23rd Jul 202011:05 amRNSSale of vaccine manufacturing assets
1st Jul 20207:00 amRNSSale of FishVet
30th Jun 20207:00 amRNSTotal Voting Rights
23rd Jun 20207:00 amRNSSale of Improve International
8th Jun 20204:54 pmRNSDirector/PDMR Shareholding - Replacement
8th Jun 202010:43 amRNSDirector/PDMR Shareholding
5th Jun 20205:50 pmRNSDirector/PDMR Shareholding
29th May 20207:00 amRNSTotal Voting Rights
29th May 20207:00 amRNSSecond Quarter and Interim Results
27th May 20208:30 amRNSEquity Development Results Webinar
19th May 20207:00 amRNSNotice of Q2 and Interim Results
6th May 202012:09 pmRNSHolding(s) in Company
30th Apr 20207:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.